October 1, 2020
“When Jan Skvarka joined biotechnology firm Trillium Therapeutics Inc. as chief executive officer, he made a big bet to reshape the company and went all-in on a cancer treatment platform. Now, he’s reaping the rewards. It was the gamble of… Continue Reading…
September 15, 2020
“Gilead Sciences will acquire biotech company Immunomedics in a $21 billion deal that will expand Gilead’s availability of cancer treatments, the companies announced on Sunday. Shares of Immunomedics surged more than 100% in premarket trading Monday. The deal will provide Gilead access to the drug Trodelvy, a… Continue Reading…
Recent Comments